» Procurement Tender News » 10079 » Tender Details

Procurement And Tender News

Tendersinfo keep you informed about the latest events in the national and international Procurement Industry. Procurement News provides in-depth coverage of the procurement industry, including contract awards, contract additions, new contract wins, mergers and acquisitions. Tendersinfo through its tender news section provides an update on all domestic and global tendering opportunities, invitation to bid & trade leads.

United States : Announces Appointment of Jarlath Keating as President and Chief Executive Officer

Publish Date : 14-Nov-2018

ABL, Inc. (ABL), a leading global contract research and manufacturing service provider to the biopharmaceutical industry, announces the appointment of Jarlath Keating as the new President and Chief Executive Officer of ABL, succeeding Dr. Thomas VanCott.

Mr. Keating recently joined ABL as Chief Commercial Officer and brings over 25 years of experience to the organization. Prior to joining ABL, Mr. Keating served as the Vice President of Global Commercial Operations for MilliporeSigmas Process Solutions Services division, leading the BioReliance biological safety testing and biomanufacturing services divisions. In this role, he oversaw the aggressive expansion of services to customers in North America, Europe and Asia Pacific. Mr. Keating has also held commercial leadership positions with HyClone and Life Technologies and technical roles at Lonza Biologics.

His appointment is a clear reflection of ABLs commitment to a long-term global expansion strategy, capitalizing on the value that ABLs scientific and manufacturing teams bring to its worldwide customer base.

We are extremely grateful for the dedicated leadership and invaluable contributions provided by Dr. VanCott during his 10-year tenure as CEO, Mr. Keating stated. It is a huge honor to lead a company with the pedigree of ABL, and I look forward to building on the solid foundation that has been laid in recent years.

We are very enthusiastic about Jarlath Keating taking over the leadership of ABL. This will enable us to strengthen our service to our customers and accelerate the strategic development of the company, said Hedi Ben Brahim, VP for Immunotherapy at Institut Mrieux and Chairman of the Board of ABL.

Go to previous page

Whats app